Bayer Seeks Fees After $155M Hemophilia Drug IP Verdict
Bayer pushed a Delaware federal court Friday to have a Takeda Pharmaceutical unit cover its legal costs on top of its $155 million jury verdict for patent infringement of a hemophilia...To view the full article, register now.
Already a subscriber? Click here to view full article